BCG’s health care industry experts will be on the ground in San Francisco January 8 through 11 during the 2024 J.P. Morgan Healthcare Conference to share insights on trends shaping the industry now and in the year ahead.
The J.P. Morgan Healthcare Conference is the largest health care investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community. BCG is thrilled to be back in San Francisco with programming coinciding with this year’s conference to explore the latest trends impacting the industry.
We’ll be in San Francisco during the 2024 J.P. Morgan Healthcare Conference to connect with R&D, business, and corporate development leaders on the 2024 outlook for the health care industry. Our experts bring a wealth of experience and deep expertise on topics at the forefront of health care leaders’ agendas in the year ahead, including:
We look forward to discussing how trends in the biopharmaceutical, medical device and technology, payer and provider, and private equity sectors are evolving. BCG’s programming is by invitation only, but stay tuned here for insights from the event.
Explore our latest thinking on topics impacting the health care industry.
Leaders need to understand the growing range of AI applications—and how to capitalize on their potential while avoiding the risks.
To realize the promise and potential for GenAI, medtech executives must make swift and targeted efforts.
The technology has a range of uses in medtech, and the main challenge is knowing how and where to start. Here are 60 ways to generate quick wins.
Implementing GenAI is not easy in an industry with a complex value chain and intensive regulatory oversight. Companies will wrestle with both choice and complexity.
BCG experts interview one of the world’s largest biopharmaceutical companies to discuss their bold “Play to Win” strategy and the role of AI in innovation.
BCG sits down in an interview with Richard Francis, CEO of Teva, to discuss the company’s bold and thoughtful strategy for advancing health care.
CCO Everett Cunningham sits down with BCG’s Torben Danger to explain how Exact Sciences is addressing the challenges of spreading colon cancer awareness.
BCG’s new annual report identifies the modalities that are progressing most rapidly and those that hold the greatest promise for patient outcomes and company revenues.
Three new provisions concerning Medicare prescription drug prices have major ramifications for companies and the broader health care ecosystem.
To retain target biotech company employees—arguably as vital to success as the pipeline being acquired—biopharmas need talent strategies that focus on three key areas.
Medtech management teams face an unfamiliar list of questions. The players that can successfully navigate the challenging terrain will be the winners of the 2020s.
Rather than focusing on discrete products, companies should develop platforms based on modular designs, with hardware and software that can be continuously upgraded.
Medical technology companies play a big part in health care’s carbon emissions problem, both at the patient and provider levels. Fortunately, these firms can reduce their footprint affordably.
Some of BCG's best advice to help provider, payer, biopharma, and medtech executives address the challenges and changes affecting the health care sector.
The latest technologies hold tremendous promise for health care, but they also pose significant challenges. Not all organizations are prepared to take advantage of the tech trends.
A suite of improvement levers provides the basis for designing a health care payers’ customized productivity transformation.
Joaquin Duato, chairman and CEO of Johnson & Johnson, and Dr. Bernd Montag, CEO of Siemens Healthineers, highlight three top priorities for CEOs this year: strategizing for growth, building financial resilience, and delivering societal impact through sustainability and health equity.
Our industry experts explore the contributions of biotechs, AI natives, and academics in drug discovery; they also discuss medtech's increasing investment in end-to-end solutions and the evolving M&A landscape.
